Across biomedical research, there is growing recognition that neither animal studies nor new approach methodologies (NAMs) can fully answer the same biological questions on their own. While governments and regulators are encouraging greater use of human-relevant models, drug development still depends on understanding how a compound behaves within a living, adaptive system over time.
Animal research remains essential in many areas, but it is increasingly clear that it must be more humane, efficient, and selective. Traditional in vivo studies rely heavily on blood draws, imaging, biopsies, or terminal endpoints, producing intermittent snapshots rather than continuous insight. Transient biological events, adaptive responses, and delayed effects are often missed entirely.
In parallel, NAMs such as organoids, organs-on-chips, and computational models have advanced rapidly. These tools offer powerful mechanistic insight into specific tissues or pathways, but they operate outside the full physiological context of a living organism. They cannot capture the integrated, time-dependent interplay between immune, metabolic, neuroendocrine, and stress responses that often determines whether a therapy ultimately succeeds or fails.
It is within this gap — between fragmented snapshots and simplified models — that Efferent Labs positions its technology. The company’s platform allows researchers to observe how drugs interact with complex systems as they adapt and respond over time — while significantly reducing the number of animals required to generate meaningful data.
Listening to biology in real time
Efferent Labs’ platform, known as CytoComm, is a biologically based implantable electronic device (BIED) that combines living cells with miniaturized photonic and wireless electronics. Rather than relying on fixed chemical sensors or predefined analyte panels, the system uses engineered living cells to provide in vivo, real-time monitoring of intra-cellular processes.
The Biosensor System is an in-vivo, real time monitoring system for biological signaling and cellular responses.
CREDIT: EFFERENT LABS
At the core of the device is a small biochamber that houses the sensor cells. The chamber is sealed with a permeable membrane that allows nutrients, signaling molecules, and interstitial fluids from the surrounding tissue to pass through, while protecting the cells from immune attack. Once implanted subcutaneously, the device rapidly integrates with the local vascular environment, exposing the cells to systemic biological signals as they naturally circulate through the body.
What used to require 20 or 30 animals can now be achieved with six, eight, or even just four, depending on how frequently you sample. It’s an exceptional increase in efficiency.
—Bill Rader, Efferent Labs
The sensor cells are genetically engineered so that activation of specific intracellular pathways — such as inflammatory, stress, or injury-related signaling — triggers a fluorescent response. An integrated photonic system detects these signals in situ, effectively functioning as a miniaturized microscope. The data are then transmitted wirelessly to software that streams and visualizes biological activity in real time.
"With the amount of data we can collect from each animal, the statistical relevance is remarkable,” Bill Rader, CEO of Efferent Labs, told DDN. “What used to require 20 or 30 animals can now be achieved with six, eight, or even just four, depending on how frequently you sample. It’s an exceptional increase in efficiency."
This approach transforms preclinical studies from a series of isolated timepoints into a continuous biological record. Researchers can observe when a response begins, how quickly it escalates, whether it adapts or resolves, and whether secondary effects emerge later — insight that is difficult or impossible to obtain using conventional in vivo endpoints or current NAMs.
From ailment to start-up
For Rader, the vision is deeply personal. Living with multiple sclerosis and undergoing standard monoclonal antibody treatments, he became acutely aware of the limitations of one-size-fits-all dosing.
"I’m six-foot-one, 215 pounds, sitting next to a 110-pound female patient from Asia, and we’re getting the same dose," he explained. "Who’s getting overdosed, who’s underdosed? This is a way to help patients like myself."
The company’s origins also trace back to cofounder Spencer Rosero, an electrocardiologist at the University of Rochester Medical Center, who saw the consequences of limited monitoring firsthand. In the early 2000s, he saw patients who arrived feeling unwell but appeared normal on all standard tests — only to return two days later in the emergency room with a heart attack. Rader recalled, “He said, ‘There has to be a way to understand what the body is telling us. Why aren’t we listening?’ That question is where this all began.”
The Biosensor System is small enough to balance on a fingertip.
CREDIT: EFFERENT LABS
Rader joined Rosero in 2012, and together they began experimenting with implantable biosensors. Their first prototypes were the size of a microwave oven, designed simply to prove that living cells could survive and function in vivo. Over time, they miniaturized the device, optimized cell viability, and transitioned from wired setups to wireless Bluetooth implants that transmit real-time biological data without repeated handling or stress for the animals.
"When we started this, the first people laughed at us," Rader said. "They said you can’t keep cells alive for three days like that. But now we can maintain robust, functional cells for 31 days in vivo, giving us continuous, reliable biological data."
Since then, Efferent Labs has secured key funding and partnerships to advance CytoComm. The company received a $500,000 grant from Buffalo’s 46North accelerator in 2014, and has earned four grants from the University at Buffalo Center for Advanced Technology totaling $107,000. Collaborations with Evotec helped optimize and validate targeted pathways, while a partnership with W. L. Gore & Associates explored advanced materials to extend cell viability for long-term, implantable biosensing.
The goal beyond preclinical testing
While Efferent Labs’ platform is currently focused on preclinical studies, the long-term vision extends to real-time monitoring and intervention in humans. By capturing dynamic biological responses continuously, the technology could enable physicians to detect adverse events or therapy responses before they become clinically apparent.
The beauty of our platform is its flexibility. You put the cells in there that you want to see, and it tells you what’s happening. The potential applications are as broad as human disease itself.
—Bill Rader, Efferent Labs
Alex Drew, the Chief Operating Officer at Efferent Labs, emphasized the platform’s adaptability. "Our long-term goal is for the device to be implanted in the body. It could sense relevant signals and notify the patient — or even deliver therapy — before an adverse event occurs."
For example, in cardiovascular care, a high-risk patient could have a sensor implanted to detect early molecular signals of inflammation or cardiac stress. Alerts could notify the patient or clinician immediately, potentially preventing a heart attack before it occurs. Similarly, in oncology, the device could monitor an individual’s response to chemotherapy in real time, guiding dose adjustments tailored to their biology and reducing toxicity.
“The beauty of our platform is its flexibility. You put the cells in there that you want to see, and it tells you what’s happening. The potential applications are as broad as human disease itself,” said Rader.
By bridging the gap between simplified models and full, living systems, Efferent Labs’ technology could redefine how researchers and clinicians understand biology. What begins as a tool to optimize preclinical studies may one day translate into real-time, patient-centered monitoring. The same principles that allow scientists to observe systemic drug responses in animals could eventually help physicians detect adverse events, personalize therapy, and intervene before illness escalates.
